Promising research is currently underway to use humanized bispecific single-domain antibodies

[spi3]

I was wondering if anyone has seen this new trial for applicable candidates

cllsociety.org/2022/11/ash-...

ASH 2021: Bispecific Vγ9Vδ2-T and Type 1 NKT Cell Engager Lava-051 As First-in-Class Clinical Candidate to Target CD1d Expressing CLL, MM and AML

November 18, 2022

INTRODUCTION:

Very complex, promising research is currently underway to use humanized bispecific single-domain antibodies (bsVHH). But, unfortunately, harnessing the immune system can get very complicated. This article introduces an experimental antibody with a novel approach to fighting CLL/SLL.

These antibodies engage different sub-types of T-lymphocytes to treat chronic lymphocytic leukemia/small lymphocytic leukemia CLL/SLL.

In this study, LAVA-51 bsVHH has been shown to stimulate both type 1 natural killer T cells (NTK) and Vγ9Vδ2-T type T-cells to kill CLL/SLL cells with no off-target toxicity. These two types of T cells have significant killing capacity against malignant B cells, so engaging them makes great sense...

[Dahlia7]

I think it sounds incredibly promising and will be asking my doctor about it. I read the article yesterday from the CLL newsletter and was pretty excited especially the part about virtually no side effects. I hope it lives up to our expectations. Tony

[spi3 in reply to Dahlia7]

Please keep us informed of what your Dr says. Also I asked my husband's team about it and they haven't heard of the study and that it will take some to see the results

[Hidden]

clinicaltrials.gov/ct2/show...

[neurodervish]

Tumor Lysis Syndrome can be dealt with prophylacticlally with allopurinol. cancernetwork.com/view/how-...